Atea Pharmaceuticals has reported top line results from its Phase III C-BEYOND trial in North America, assessing the once-daily fixed-dose BEM/RZR combination for chronic HCV infection.

The post Atea reports positive topline results in Phase III hepatitis C study appeared first on Clinical Trials Arena.